Page 1

November 1 , 2021 Cabaletta BioⓇ Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update - Dose dependent increase in DSG3 - CAART persistence observed in the third dose cohort with 500 million DSG3 - CAART cells relative to the first two low dose cohorts in DesCAARTes ™ Phase 1 clinical trial throughout the 28 days following infusion - - No dose limiting toxicities ( DLTs ) or clinically relevant adverse events observed as of October 31 , 2021 , in the first three dose cohorts - - Dosing initiated in fourth patient cohort at a dose of 2.5 billion DSG3 - CAART cells DesCAARTes ™ trial advancing toward key milestones ; top - line biologic activity data from first two low dose cohorts expected to be announced in 4Q21 - - Lead preclinical program , MuSK - CAART , Investigational New Drug ( IND ) submission on track for 4Q21 ; PLA2R - CAART preclinical data to be presented at the American Society of Nephrology's Kidney Week that show potential as a precision therapy for patients with PLA2R membranous nephropathy - - Ended the quarter with $ 119.3M in cash , extending the cash runway to fund operations through at least 1Q23- PHILADELPHIA , Nov. 01 , 2021 ( GLOBE NEWSWIRE ) -- Cabaletta Bio , Inc. ( Nasdaq : CABA ) , a clinical - stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell - mediated autoimmune diseases , today reported financial results for the third quarter ended September 30 , 2021 , and provided a business update . " The DesCAARTesTM trial for DSG3 - CAART for patients with mucosal - dominant pemphigus vulgaris has demonstrated encouraging momentum , with continued strong patient enrollment as well as new site and investigator engagement . Dose dependent increases in DSG3- CAART persistence in the third cohort through 28 days following infusion have been observed , as well as the continued absence of any DLTs or clinically relevant adverse events for the first three cohorts as of October 31 , 2021. Our next anticipated data readout will include top - line biologic activity data from the first two low dose cohorts , which we expect to announce in the fourth quarter of 2021. We look forward to continuing to generate data on potential biologic activity as we proceed to higher dosing cohorts , with the goal of providing a targeted , highly effective , and potentially curative , therapy without generalized immunosuppression , " said Steven Nichtberger , M.D. , Chief Executive Officer and Co- founder of Cabaletta . " We are operating under a strengthened balance sheet as a result of $ 32 million in additional gross proceeds through our “ at - the - market ” ( ATM ) equity offering program . In addition to advancing the DesCAARTes TM trial , we are also focused on growing our novel pipeline . To that end , we expect to progress our two lead preclinical programs in